Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2

Introduction: Hepatocellular carcinoma is one of the most common cancers that affected human in more than half of the world population. Although there is yet any alternatives treatment found for this disease, the antitumor property of thymoquinone has been well studied in most of cancer cell lines....

Full description

Saved in:
Bibliographic Details
Main Authors: Mustafa Azmy, Nurfahima, Haron, Aminah Suhaila, Syed Alwi, Sharifah Sakinah
Format: Article
Language:English
Published: Faculty of Medicine and Health Sciences, Universiti Putra Malaysia 2019
Online Access:http://psasir.upm.edu.my/id/eprint/70036/1/2019070210002006_MJMHS_SP2_2019.pdf
http://psasir.upm.edu.my/id/eprint/70036/
https://medic.upm.edu.my/upload/dokumen/2019070210002006_MJMHS_SP2_2019.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Putra Malaysia
Language: English
id my.upm.eprints.70036
record_format eprints
spelling my.upm.eprints.700362019-08-16T00:38:46Z http://psasir.upm.edu.my/id/eprint/70036/ Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2 Mustafa Azmy, Nurfahima Haron, Aminah Suhaila Syed Alwi, Sharifah Sakinah Introduction: Hepatocellular carcinoma is one of the most common cancers that affected human in more than half of the world population. Although there is yet any alternatives treatment found for this disease, the antitumor property of thymoquinone has been well studied in most of cancer cell lines. Nonetheless, poor bioavailability of TQ limits its efficiency. The encapsulation form of TQ, TQ-NLC is suggested to enhance its bioavailability as well as cytotoxicity towards cancer cells via increasing resistance time and targeting drug to specified location in the body. Therefore, it is a great advantage to look at the effects of TQ-NLC towards HepG2. This study is design to look at the anti-proliferative effect of TQ-NLC on HepG2 and the changes in the cells morphology. Methods: Both cells were bought from ATCC and cultured in supplemented DMEM. Cell viability was determined via MTT assay. Pro-apoptotic effect of TQ-NLC was further confirmed with Annexin V staining. Morphology hallmarks of apoptosis of treated cells were also analysed using inverted microscope. Images were captured at 24, 48 and 72 hours. Results: TQ-NLC was very potent towards HepG2 compared to 3T3 with the relative IC50 of 25 μM. TQ-NLC was also more potent compared to the non-encapsulated form, TQ. Further analysis confirmed that TQ-NLC capable to increase the percentage of apoptotic cells in time-dependent manner. Qualitatively, all treated cells displayed the apoptosis morphology with increasing concentration and longer time-point. Conclusion: TQ-NLC showed greater cytotoxic effects towards HepG2 which was further confirmed with the morphological analysis. Faculty of Medicine and Health Sciences, Universiti Putra Malaysia 2019 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/70036/1/2019070210002006_MJMHS_SP2_2019.pdf Mustafa Azmy, Nurfahima and Haron, Aminah Suhaila and Syed Alwi, Sharifah Sakinah (2019) Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2. Malaysian Journal of Medicine and Health Sciences, 15 (SP2). pp. 38-43. ISSN 1675-8544; ESSN: 2636-9346 https://medic.upm.edu.my/upload/dokumen/2019070210002006_MJMHS_SP2_2019.pdf
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
language English
description Introduction: Hepatocellular carcinoma is one of the most common cancers that affected human in more than half of the world population. Although there is yet any alternatives treatment found for this disease, the antitumor property of thymoquinone has been well studied in most of cancer cell lines. Nonetheless, poor bioavailability of TQ limits its efficiency. The encapsulation form of TQ, TQ-NLC is suggested to enhance its bioavailability as well as cytotoxicity towards cancer cells via increasing resistance time and targeting drug to specified location in the body. Therefore, it is a great advantage to look at the effects of TQ-NLC towards HepG2. This study is design to look at the anti-proliferative effect of TQ-NLC on HepG2 and the changes in the cells morphology. Methods: Both cells were bought from ATCC and cultured in supplemented DMEM. Cell viability was determined via MTT assay. Pro-apoptotic effect of TQ-NLC was further confirmed with Annexin V staining. Morphology hallmarks of apoptosis of treated cells were also analysed using inverted microscope. Images were captured at 24, 48 and 72 hours. Results: TQ-NLC was very potent towards HepG2 compared to 3T3 with the relative IC50 of 25 μM. TQ-NLC was also more potent compared to the non-encapsulated form, TQ. Further analysis confirmed that TQ-NLC capable to increase the percentage of apoptotic cells in time-dependent manner. Qualitatively, all treated cells displayed the apoptosis morphology with increasing concentration and longer time-point. Conclusion: TQ-NLC showed greater cytotoxic effects towards HepG2 which was further confirmed with the morphological analysis.
format Article
author Mustafa Azmy, Nurfahima
Haron, Aminah Suhaila
Syed Alwi, Sharifah Sakinah
spellingShingle Mustafa Azmy, Nurfahima
Haron, Aminah Suhaila
Syed Alwi, Sharifah Sakinah
Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2
author_facet Mustafa Azmy, Nurfahima
Haron, Aminah Suhaila
Syed Alwi, Sharifah Sakinah
author_sort Mustafa Azmy, Nurfahima
title Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2
title_short Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2
title_full Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2
title_fullStr Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2
title_full_unstemmed Thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, HepG2
title_sort thymoquinone-loaded nanostructured lipid carrier reduces proliferation of human liver cancer cells, hepg2
publisher Faculty of Medicine and Health Sciences, Universiti Putra Malaysia
publishDate 2019
url http://psasir.upm.edu.my/id/eprint/70036/1/2019070210002006_MJMHS_SP2_2019.pdf
http://psasir.upm.edu.my/id/eprint/70036/
https://medic.upm.edu.my/upload/dokumen/2019070210002006_MJMHS_SP2_2019.pdf
_version_ 1643839630590607360